Observed Signal · Nov 19, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 3/5 · Sentiment: Positive

London AI drug discovery startup Boltz raises $110M Series A

Executive Signal Summary

Boltz, a London-based AI startup focused on drug discovery, has raised a $110 million Series A funding round, less than a year after emerging from stealth. The company develops AI models to predict protein-drug interactions and design new molecules, accelerating early-stage drug discovery. The round was led by Bessemer Venture Partners, with participation from existing investors including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, and Obvious Ventures, as well as new investors Greycroft, F-Prime Capital, Hummingbird, and Benchling. Nvidia had previously invested earlier this year. Boltz has announced collaborations with major pharmaceutical companies such as Pfizer, GSK, Takeda, and Bristol Myers Squibb. The funding will support further model development and investment in compute and data infrastructure.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

This funding round highlights the growing investment in AI-driven drug discovery, a sector that leverages advanced AI models and infrastructure, with implications for AI model development and compute demand relevant to AdTech's AI adoption.

MARKET SIGNALS

Track Bessemer Venture Partners (BVP) Signals & Strategic Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • Boltz raised a $110 million Series A funding round.
  • The round was led by Bessemer Venture Partners, with participation from Greycroft, F-Prime Capital, Hummingbird, and Benchling.
  • Existing investors include Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, and Obvious Ventures.
  • Boltz has announced collaborations with Pfizer, GSK, Takeda, and Bristol Myers Squibb.
  • The company employs 40 AI researchers in London's King's Cross district.

Connected Companies & Entities

“existing investors including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures participating.”

“New investors include Greycroft, F-Prime Capital, Hummingbird and Benchling.”

“Nvidia, which also announced an investment earlier this year during Jensen Huang’s visit to the UK.”

“Boltz has announced collaborations with Pfizer, GSK, Takeda and Bristol Myers Squibb.”

Ontology Mapping & Concepts

Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: Tech.eu (European Tech & Deals)•Published: Nov 19, 2026
Original Coverage Title: “London-based Boltz raises $110M Series A”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

AI in Drug DevelopmentOct 27, 2026

Atlas Bio Raises $12.5M for AI Clinical Trial Simulations

Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.

Read assessment
FundingSep 23, 2026

Anthropic and Nvidia back Basecamp Research in $140M Series C

London-based life sciences startup Basecamp Research has raised $140 million in a Series C funding round led by venture firm S32. Nvidia's venture arm NVentures and Anthropic's Anthology Fund participated, alongside other new and returning investors. The company uses AI and biodiversity data to design new medicines, with a focus on in vivo cell therapy. The funds will be used to train next-generation AI models and advance its pipeline of AI-designed therapeutics. Basecamp has raised $225 million in total.

Read assessment
AI Drug DiscoveryNov 17, 2026

Isomorphic Labs raises $5 billion for AI drug discovery

Isomorphic Labs, the AI-driven drug discovery company founded by Sir Demis Hassabis, has raised a $5 billion (€4.5 billion) Series C round. Co-led by Greenoaks and Sequoia Capital, the round also saw participation from Andreessen Horowitz, Alphabet, and existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. The funding will accelerate the development of its AI drug design engine (IsoDDE), expand foundational biology models, and advance its therapeutic pipeline toward clinical trials. This investment highlights the massive capital flowing into AI-driven drug discovery, a sector that raised a record $23.2 billion in 2026. Isomorphic's round dwarfs other European AI drug discovery startups, which collectively raised approximately €148.2 million in the same period.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for Bessemer Venture Partners (BVP) & competitors in your briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context